Literature DB >> 25795182

Comparison of osteoradionecrosis of the jaw after superselective intra-arterial chemoradiotherapy versus conventional concurrent chemoradiotherapy of oral cancer.

Wataru Kobayashi1, Beng Gwan Teh2, Hiroto Kimura3, Sinya Kakehata4, Hideo Kawaguchi4, Yoshihiro Takai5.   

Abstract

PURPOSE: The purpose of the present study was to compare the incidence of osteoradionecrosis between superselective intra-arterial chemoradiotherapy and intravenous chemoradiotherapy and to verify the risk factors for osteoradionecrosis.
MATERIALS AND METHODS: Of the 79 patients with oral cancer, 40 were treated with intra-venous chemoradiotherapy and 39 were treated with superselective intra-arterial chemoradiotherapy. The incidence of, and risk factors for, osteoradionecrosis were evaluated using statistical analysis.
RESULTS: Of the 79 patients, 4 (10%) of 40 in the intravenous chemoradiotherapy and 7 (17.9%) of 39 in the superselective intra-arterial chemoradiotherapy group developed osteoradionecrosis of the jaw. No significant difference was found between the 2 groups. Although the chemoradiotherapy methods, anatomic tumor location, smoking behavior, alcohol consumption, condition of teeth, teeth extraction before radiation, and progression of dental caries were considered predisposing factors for the occurrence of osteoradionecrosis, only progressive dental caries resulted in a significant difference for osteoradionecrosis.
CONCLUSIONS: The present study is the first report comparing the incidence of osteoradionecrosis between superselective intra-arterial chemoradiotherapy and intravenous chemoradiotherapy. The administration methods of anticancer drugs were not related to the incidence of osteoradionecrosis in our study. From our study, dental caries is the most important risk factor for osteoradionecrosis; therefore, a radiation caries prevention program is crucial to control osteoradionecrosis.
Copyright © 2015 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25795182     DOI: 10.1016/j.joms.2014.11.016

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

1.  Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.

Authors: 
Journal:  Radiother Oncol       Date:  2017-07-18       Impact factor: 6.280

Review 2.  Oral management strategies for radiotherapy of head and neck cancer.

Authors:  Yumiko Kawashita; Sakiko Soutome; Masahiro Umeda; Toshiyuki Saito
Journal:  Jpn Dent Sci Rev       Date:  2020-02-20

Review 3.  Dental extraction, intensity-modulated radiotherapy of head and neck cancer, and osteoradionecrosis : A systematic review and meta-analysis.

Authors:  Panagiotis Balermpas; Janita E van Timmeren; David J Knierim; Matthias Guckenberger; Ilja F Ciernik
Journal:  Strahlenther Onkol       Date:  2022-01-14       Impact factor: 3.621

4.  Risk factors for osteoradionecrosis of the jaw in patients with oral or oropharyngeal cancer: Verification of the effect of tooth extraction before radiotherapy using propensity score matching analysis.

Authors:  Yuka Kojima; Mitsunobu Otsuru; Takumi Hasegawa; Nobuhiro Ueda; Tadaaki Kirita; Shin-Ichi Yamada; Hiroshi Kurita; Yasuyuki Shibuya; Madoka Funahara; Masahiro Umeda
Journal:  J Dent Sci       Date:  2021-11-20       Impact factor: 3.719

5.  Impact of superselective intra-arterial and systemic chemoradiotherapy for gingival carcinoma; analysis of treatment outcomes and prognostic factors.

Authors:  Yuki Mukai; Yuichiro Hayashi; Izumi Koike; Toshiyuki Koizumi; Madoka Sugiura; Senri Oguri; Shoko Takano; Mitomu Kioi; Mizuki Sato; Kenji Mitsudo; Masaharu Hata
Journal:  BMC Cancer       Date:  2020-11-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.